CHEO Research Institute Logo
Decrease Text SizeIncrease Text SizeFacebookTwitterYoutube

researchers working in a lab

Margaret Lawson photo of Margaret Lawson
Senior Scientist, Evidence to Practice Research Program,
CHEO Research Institute
Pediatric Endocrinologist, Division of Endocrinology and Metabolism,
Department of Pediatrics, CHEO
Full Professor, Department of Pediatrics,
Faculty of Medicine, University of Ottawa
Director, JDRF Canadian Clinical Trial Network (CCTN)
Centre for Type 1 Diabetes Research
Medical Director, Family Decision Services,
CHEO Research Institute
613-737-7600 Ext. 2411
Research Practice Areas:
Current Research:

As Director of the Juvenile Diabetes Research Foundation/CCTN Centre for Type 1 Diabetes Research, Dr. Lawson is developing and participating in multicentre pediatric clinical trials. She is principal investigator of the CGM TIME Trial, a multicentre RCT which is the first study to examine the relationship between timing of CGM initiation, readiness for behaviour change, and subsequent CGM adherence in pump naïve children and adolescents. She has mentored two JDRF/CCTN Fellowship Research Award Programs with Drs. E Heffernan and K Verbeeten. She was the deputy principal investigator for TRIGR Canada, the principal investigator at the TRIGR Canada Coordinating Centre and the TRIGR Ottawa Clinical Site. TRIGR was an international 15 country multicentre trial which showed conclusively that changing the cow’s milk proteins in baby formula did not prevent type 1 diabetes in children who are at genetic risk. Dr. Lawson is the Co-Principal Investigator and Clinical Lead in Trans Youth Can! - a 9 site, pan Canadian CIHR-funded study which is examining medical, social and family outcomes of hormone interventions for transgender and gender non binary youth. She remains the Ottawa principal investigator for the Type 1 Diabetes TrialNet Network with the Natural History Study Pathway to Prevention, the Oral Insulin Study and the Long-Term Investigative Follow-Up in TrialNet (LIFT).

The results of the 14 Year TRIGR study were published in the Journal of the American Medical Association (JAMA) on January 2, 2018. Read the press release here.

photo of dr lawson in youtube video 
A long-asked research question has finally been answered: is it possible to prevent Type 1 diabetes by altering the kind of formula that infants are exposed to in the first months of life? In this CHEO Discovery Minute, Margaret Lawson shares the results of the 14-year Trial to Reduce IDDM in the Genetically at Risk (TRIGR) study.
Research Team:
Dr. Margaret Lawson is a pediatric endocrinologist at CHEO, Senior Investigator at the CHEO Research Institute, and Professor of Pediatrics at the University of Ottawa. Her research focuses on type 1 diabetes in children and youth, its prevention, and its management – particularly the use of technologies such as insulin pump therapy and continuous glucose monitoring. Her other main research interest focuses on acquiring evidence about the medical, social and family outcomes of hormone intervention for transgender and gender non binary youth.
Sample Publications:
Perform an automatic PubMed search of Dr. Lawson's publications by accessing this link.

View Q & A
Take Action
Quick Links

Our Researchmagnifying glass

abcefg hijklmnopqrst uvwxyz